Article,
Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006
Vaccine, 27 (27): 3553--3560 (June 2009)PMID: 19464534.
DOI: 10.1016/j.vaccine.2009.03.063
Abstract
Alberta, Canada introduced the Streptococcus pneumoniae seven valent conjugate vaccine (PCV7) program for children less than 2 years of age in September 2002. We determined the rates of invasive pneumococcal disease in Alberta, Canada 2 years pre- and 4 years post-PCV7 introduction (2000-2006) as well as the rates of antibiotic resistance and serotype distribution in this same time period. Overall, PCV7 serotypes decreased 61\% from 2000 to 2006. The greatest decrease in incidence of invasive pneumococcal disease occurred in children less than 2 years of age declining from a high of 96.7/100,000 (2000) to 25.8/100,000 (2006) (P\textless0.0001). Non-susceptibility of S. pneumoniae isolates to penicillin dropped significantly from 14\% in 2000 to 4.6\% in 2006 (P\textless0.0001). Non-susceptible erythromycin isolates also decreased from 8.8\% (2000) to 5.8\% (2006) (P=0.13). The introduction of PCV7 in Alberta, Canada has decreased the incidence of invasive pneumococcal disease in Alberta as well as resulting in a decrease in antibiotic resistance over this same time frame, principally for penicillin resistance.
Tags
- adolescent,
- adult,
- aged,
- canada,
- child,
- combination
- erythromycin,
- factors,
- humans,
- infant,
- microbial
- middle
- penicillins,
- pneumococcal
- pneumoniae,
- preschool,
- sensitivity
- serotyping,
- streptococcus
- tests,
- time
- vaccines,
- {trimethoprim-sulfamethoxazole}
